BR112018012641A2 - molécula de penetração de célula portadora de fármaco, métodos para facilitar a incorporação de um composto biologicamente ativo (bac) em uma célula, para melhorar a biodisponibilidade de um fármaco ou bac, para introduzir um fármaco ou bac em um sítio e para alterar a expressão de um gene endógeno ou exógeno, e, composição. - Google Patents
molécula de penetração de célula portadora de fármaco, métodos para facilitar a incorporação de um composto biologicamente ativo (bac) em uma célula, para melhorar a biodisponibilidade de um fármaco ou bac, para introduzir um fármaco ou bac em um sítio e para alterar a expressão de um gene endógeno ou exógeno, e, composição.Info
- Publication number
- BR112018012641A2 BR112018012641A2 BR112018012641A BR112018012641A BR112018012641A2 BR 112018012641 A2 BR112018012641 A2 BR 112018012641A2 BR 112018012641 A BR112018012641 A BR 112018012641A BR 112018012641 A BR112018012641 A BR 112018012641A BR 112018012641 A2 BR112018012641 A2 BR 112018012641A2
- Authority
- BR
- Brazil
- Prior art keywords
- bac
- drug
- cell
- cpps
- bioavailability
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 6
- 229940079593 drug Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003937 drug carrier Substances 0.000 title abstract 2
- 238000010348 incorporation Methods 0.000 title abstract 2
- 230000035515 penetration Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- WROTXLSEMHAZEA-UHFFFAOYSA-N 4-diaminophosphoryloxymorpholine Chemical compound NP(N)(=O)ON1CCOCC1 WROTXLSEMHAZEA-UHFFFAOYSA-N 0.000 abstract 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 abstract 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 230000001588 bifunctional effect Effects 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 108700026220 vif Genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1522548.5A GB2545898B (en) | 2015-12-21 | 2015-12-21 | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| PCT/GB2016/054028 WO2017109494A1 (en) | 2015-12-21 | 2016-12-21 | Biologically active compound conjugated to a stapled or stitched peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018012641A2 true BR112018012641A2 (pt) | 2018-12-04 |
Family
ID=55311362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018012641A BR112018012641A2 (pt) | 2015-12-21 | 2016-12-21 | molécula de penetração de célula portadora de fármaco, métodos para facilitar a incorporação de um composto biologicamente ativo (bac) em uma célula, para melhorar a biodisponibilidade de um fármaco ou bac, para introduzir um fármaco ou bac em um sítio e para alterar a expressão de um gene endógeno ou exógeno, e, composição. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11541124B2 (https=) |
| EP (1) | EP3393520A1 (https=) |
| JP (2) | JP2019508481A (https=) |
| KR (1) | KR20180091920A (https=) |
| CN (1) | CN108472385A (https=) |
| AU (1) | AU2016375869B2 (https=) |
| BR (1) | BR112018012641A2 (https=) |
| CA (1) | CA3007910A1 (https=) |
| GB (1) | GB2545898B (https=) |
| WO (1) | WO2017109494A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB201711809D0 (en) * | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| WO2019070962A1 (en) | 2017-10-04 | 2019-04-11 | Ohio State Innovation Foundation | BICYCLIC PEPTIDE INHIBITORS |
| WO2019084528A1 (en) | 2017-10-27 | 2019-05-02 | Ohio State Innovation Foundation | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR ADMINISTRATION OF STAPLED PEPTIDES |
| EP3746105A4 (en) | 2018-01-29 | 2022-05-18 | Ohio State Innovation Foundation | CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN |
| WO2019157131A1 (en) * | 2018-02-07 | 2019-08-15 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
| CA3111278A1 (en) | 2018-08-31 | 2020-03-05 | Massachusetts Institute Of Technology | Ionizable lipidoids and their uses |
| EP3962933A1 (en) * | 2019-04-18 | 2022-03-09 | Dana-Farber Cancer Institute, Inc. | Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides |
| KR102544364B1 (ko) * | 2019-06-17 | 2023-06-19 | 주식회사 안단테에프엠 | Romo1 유래 항균 펩타이드 및 그 변이체 |
| KR102521182B1 (ko) * | 2020-11-06 | 2023-04-12 | 서울대학교산학협력단 | 결핵균 독소-항독소 시스템을 표적으로 하는 항균 스테이플 펩타이드 및 이의 용도 |
| WO2024069229A2 (en) | 2022-08-03 | 2024-04-04 | Sutura Therapeutics Ltd | Biologically active compounds |
| WO2025027389A1 (en) | 2023-08-03 | 2025-02-06 | Sutura Therapeutics Limited | Biologically active compounds comprising a stapled or stitched peptide |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3856406T2 (de) * | 1987-10-28 | 2000-10-19 | Howard Florey Institute Of Experimental Physiology And Medicine, Parkville | Oligonucleotid-polyamid konjugate |
| CA2693742A1 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| AU2008317566B2 (en) * | 2007-10-26 | 2014-05-01 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| WO2009149214A2 (en) | 2008-06-03 | 2009-12-10 | Aileron Therapeutics, Inc. | Compositions and methods for enhancing cellular transport of biomolecules |
| CN112574988A (zh) | 2008-10-24 | 2021-03-30 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| CA2759899A1 (en) * | 2009-04-24 | 2010-10-28 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
| JP2012532929A (ja) | 2009-07-13 | 2012-12-20 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二機能性のステープリングされたポリペプチドおよびそれらの使用 |
| WO2011111874A1 (ja) | 2010-03-11 | 2011-09-15 | 独立行政法人理化学研究所 | 細胞膜透過性ダンベル型rnaおよびその製造方法 |
| RU2664452C2 (ru) * | 2010-04-19 | 2018-08-17 | Нлифе Терапеутикс, С.Л. | Конъюгат, медицинское средство и способы лечения и/или профилактики депрессии и болезни, связанной с отложением телец Леви |
| WO2012150960A1 (en) | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Peptide oligonucleotide conjugates |
| CN103998458B (zh) | 2011-08-30 | 2018-10-09 | 医学研究理事会 | 具有中央疏水域的细胞穿透肽 |
| CN103121959B (zh) | 2011-11-21 | 2016-09-21 | 昆山市工业技术研究院小核酸生物技术研究所有限责任公司 | 化合物和核酸复合分子与核酸复合物及其制备方法和应用 |
| WO2013150338A1 (en) * | 2012-04-04 | 2013-10-10 | Centre National De La Recherche Scientifique | Stapled cell penetrating peptides for intracellular delivery of molecules |
| WO2014053879A1 (en) * | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| MX2015005328A (es) * | 2012-10-26 | 2015-09-25 | Nlife Therapeutics S L | Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas. |
| CN103626850B (zh) | 2013-04-03 | 2015-08-26 | 安徽省新星药物开发有限责任公司 | 具有细胞穿透功能的多肽及其在药物递送中的用途 |
| EP3297649B1 (en) | 2015-05-19 | 2023-10-11 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| HK1257747A1 (zh) | 2015-07-15 | 2019-10-25 | Protagonist Therapeutics Inc. | 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途 |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| GB2563875B (en) | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
-
2015
- 2015-12-21 GB GB1522548.5A patent/GB2545898B/en not_active Expired - Fee Related
-
2016
- 2016-12-21 KR KR1020187020172A patent/KR20180091920A/ko active Pending
- 2016-12-21 AU AU2016375869A patent/AU2016375869B2/en not_active Ceased
- 2016-12-21 CN CN201680073127.3A patent/CN108472385A/zh active Pending
- 2016-12-21 BR BR112018012641A patent/BR112018012641A2/pt active Search and Examination
- 2016-12-21 JP JP2018550872A patent/JP2019508481A/ja active Pending
- 2016-12-21 WO PCT/GB2016/054028 patent/WO2017109494A1/en not_active Ceased
- 2016-12-21 CA CA3007910A patent/CA3007910A1/en active Pending
- 2016-12-21 US US16/061,548 patent/US11541124B2/en active Active
- 2016-12-21 EP EP16822244.6A patent/EP3393520A1/en not_active Withdrawn
-
2022
- 2022-12-27 US US18/088,933 patent/US11944688B2/en active Active
-
2023
- 2023-02-02 JP JP2023014917A patent/JP2023055874A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200353092A1 (en) | 2020-11-12 |
| GB2545898A (en) | 2017-07-05 |
| JP2023055874A (ja) | 2023-04-18 |
| AU2016375869A1 (en) | 2018-08-09 |
| CN108472385A (zh) | 2018-08-31 |
| GB201522548D0 (en) | 2016-02-03 |
| KR20180091920A (ko) | 2018-08-16 |
| JP2019508481A (ja) | 2019-03-28 |
| EP3393520A1 (en) | 2018-10-31 |
| US11541124B2 (en) | 2023-01-03 |
| AU2016375869B2 (en) | 2023-07-13 |
| CA3007910A1 (en) | 2017-06-29 |
| US11944688B2 (en) | 2024-04-02 |
| US20230158166A1 (en) | 2023-05-25 |
| GB2545898B (en) | 2019-10-09 |
| WO2017109494A1 (en) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018012641A2 (pt) | molécula de penetração de célula portadora de fármaco, métodos para facilitar a incorporação de um composto biologicamente ativo (bac) em uma célula, para melhorar a biodisponibilidade de um fármaco ou bac, para introduzir um fármaco ou bac em um sítio e para alterar a expressão de um gene endógeno ou exógeno, e, composição. | |
| ES2653615T3 (es) | Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos | |
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| US20220313642A1 (en) | Tyrosine derivatives and compositions comprising them | |
| JP6159996B2 (ja) | ペプチドを含む医薬組成物 | |
| BR112015006828A8 (pt) | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 | |
| BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
| US20200283503A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases | |
| CN102784109B (zh) | 注射用紫杉烷类药物白蛋白纳米粒制剂及其制备方法 | |
| EP2983661A1 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| CN102626393B (zh) | 一种可溶性注射用白蛋白纳米粒制剂及其制备方法 | |
| NZ701205A (en) | Optimised subcutaneous therapeutic agents | |
| US20260027088A1 (en) | Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer | |
| AR114323A1 (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
| EP3493815A1 (en) | Formulations of fosaprepitant and aprepitant | |
| Grigoryev | Stapled peptide to enter human testing, but affinity questions remain | |
| KR20180014042A (ko) | 약물을 전달하기 위한 가교된 히알루론산 및 이를 이용한 약학적 제제 | |
| WO2017048812A1 (en) | Skin-penetrating peptides and compositions and methods of use thereof | |
| EP3548086A1 (en) | Tyrosine derivatives and compositions comprising them | |
| BR112019004210A2 (pt) | composição farmacêutica, método e kit para tratamento da deficiência de hormônio do crescimento | |
| BR112023002161A2 (pt) | Formas sólidas de dosagem de palbociclibe | |
| US12582618B2 (en) | Bis-biguanide compounds, pharmaceutical compositions and uses in managing cancer | |
| US11524000B2 (en) | Targeting Mcl-1 to enhance DNA replication stress sensitivity for cancer therapy | |
| WO2020227682A1 (en) | Treating cancer | |
| CN104027307A (zh) | 药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |